Ondansetron hydrochloride and Exemestane drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ondansetron hydrochloride and Exemestane. Common interactions include fatigue among females.

The phase IV clinical study analyzes what interactions people who take Ondansetron hydrochloride and Exemestane have. It is created by eHealthMe based on reports of 27 people who take Ondansetron hydrochloride and Exemestane from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Feb, 07, 2023

27 people who take Ondansetron hydrochloride and Exemestane together, and have interactions are studied.


What is Ondansetron hydrochloride?

Ondansetron hydrochloride has active ingredients of ondansetron hydrochloride. It is often used in nausea. eHealthMe is studying from 7,483 Ondansetron hydrochloride users for its effectiveness, alternative drugs and more.

What is Exemestane?

Exemestane has active ingredients of exemestane. It is often used in breast cancer. eHealthMe is studying from 11,685 Exemestane users for its effectiveness, alternative drugs and more.

Number of Ondansetron hydrochloride and Exemestane reports submitted per year:

Ondansetron hydrochloride and Exemestane drug interactions.

Common Ondansetron Hydrochloride and Exemestane drug interactions by gender *:

female:

  1. Fatigue
  2. Diarrhoea
  3. Cough
  4. Decreased appetite
  5. Dysgeusia
  6. Stomatitis
  7. Dyspnoea
  8. Neoplasm progression
  9. Drug intolerance
  10. Thrombocytopenia

male:

n/a

Common Ondansetron Hydrochloride and Exemestane drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Dyspnoea
  2. Malignant neoplasm progression
  3. Neoplasm
  4. Pain in extremity

50-59:

  1. Alopecia
  2. Blister
  3. Cough
  4. Drug therapeutic incompatibility
  5. Dyspnoea
  6. Weight decreased

60+:

  1. Fatigue
  2. Diarrhoea
  3. Neoplasm progression
  4. Thrombocytopenia
  5. Blood glucose increased
  6. Decreased appetite
  7. Abdominal discomfort
  8. Arthralgia
  9. Back pain
  10. Bone disorder

Common conditions people have *:

  1. Breast Cancer Metastatic: 13 people, 48.15%
  2. Breast Cancer Female: 4 people, 14.81%
  3. Breast Cancer Stage Iv: 2 people, 7.41%

* Approximation only. Some reports may have incomplete information.

Do you take Ondansetron hydrochloride and Exemestane?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Ondansetron hydrochloride and Exemestane:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ondansetron hydrochloride side effects:

Browse all side effects of Ondansetron hydrochloride:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Exemestane side effects:

Browse all side effects of Exemestane:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ondansetron hydrochloride interactions:

Browse all interactions between Ondansetron hydrochloride and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Exemestane interactions:

Browse all interactions between Exemestane and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ondansetron hydrochloride and exemestane (the active ingredients of Ondansetron hydrochloride and Exemestane, respectively), and Ondansetron hydrochloride and Exemestane (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Ondansetron hydrochloride and Exemestane.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: